Verastem, Inc. (VSTM) News
Filter VSTM News Items
VSTM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VSTM News Highlights
- VSTM's 30 day story count now stands at 4.
- Over the past 22 days, the trend for VSTM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- RAMP are the most mentioned tickers in articles about VSTM.
Latest VSTM News From Around the Web
Below are the latest news stories about VERASTEM INC that investors may wish to consider to help them evaluate VSTM as an investment opportunity.
Verastem Oncology Announces Reverse Stock SplitBOSTON, May 31, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock. Verastem’s stockholders approved an amendment to Verastem’s Restated Certificate of Incorporation (as amended, the "Amended Charter") to effect the reverse stock split at Verastem’s Annual Meeting of Stockholders held on May 15, 2023. The re |
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and DefactinibBOSTON, May 25, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced updated data from Part A of the ongoing registration-directed RAMP 201 (ENGOTov60/GOG3052) trial evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer (LGSOC). |
Verastem Oncology Appoints Karin Tollefson, PhD, to Board of DirectorsBOSTON, May 16, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Karin Tollefson to its Board of Directors, effective May 15, 2023. Dr. Tollefson is the Senior Vice President and Head of Global Medical Affairs at Seagen Inc. where she has led the medical organization through the successful launches of three practice-changing medicines and established a global medical affairs organi |
Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressBOSTON, May 09, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent progress. |
Strong week for Verastem (NASDAQ:VSTM) shareholders doesn't alleviate pain of five-year lossIt's nice to see the Verastem, Inc. ( NASDAQ:VSTM ) share price up 15% in a week. But will that repair the damage for... |
Verastem Oncology to Participate in Upcoming Investor ConferencesBOSTON, May 01, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: |
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual MeetingBOSTON, April 26, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that an abstract highlighting updated interim results from Part A of the ongoing Phase 2, registration-directed RAMP 201 trial evaluating avutometinib (VS-6766) and defactinib in patients with low-grade serous ovarian cancer (LGSOC) has been selected for a presentation in a Poster Discussion Session at the upcoming American Society |
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology DaysBOSTON, April 18, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will present at the Stifel 2023 Virtual Targeted Oncology Days on Tuesday, April 25, 2023 at 2:30 p.m. ET. |
7 Very Undervalued Penny Stocks to Buy in April 2023Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option. |
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, April 06, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 17,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an |